Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

Open access
Wang, Pengju, Li, Xiaozhu, Wang, Jiwei, Gao, Dongling, Li, Yuenan, Li, Haoze, Chu, Yongchao, Zhang, Zhongxian, Liu, Hongtao, Jiang, Guozhong, Cheng, Zhenguo, Wang, Shengdian, Dong, Jianzeng, Feng, Baisui, Chard, Louisa S., Lemoine, Nicholas R., Wang, Yaohe · 2017 · Nature Communications

Abstract

Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor immunotherapy. However, potentially lethal toxicity associated with systemic administration of IL-12 precludes its clinical application. Here we redesign the molecule in such a way that its anti-tumor efficacy is not compromised, but toxic effects are eliminated. Deletion of the N-terminal signal peptide of IL-12 can effect such a change by preventing IL-12 secretion from cells. We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (ns) IL-12 to tumor cells and examine the therapeutic and toxic effects in Syrian hamster models of pancreatic cancer (PaCa). Strikingly, intraperitoneal delivery of Ad-TD-nsIL-12 significantly enhanced survival of animals with orthotopic PaCa and cured peritoneally disseminated PaCa with no toxic side effects, in contrast to the treatment with Ad-TD expressing unmodified IL-12. These findings offer renewed hope for development of IL-12-based treatments for cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-01385-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 174

Metadata

Authors
Wang, P., Li, X., Wang, J., Gao, D., Li, Y., Li, H., Chu, Y., Zhang, Z., Liu, H., Jiang, G., Cheng, Z., Wang, S., Dong, J., Feng, B., Chard, L. S., Lemoine, N. R., & Wang, Y.
Venue
Nature Communications
Published
2017-11-09
Volume
8
Issue
1
Pages
1395-1395
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2767171253
Cited by
174
References
3
FWCI
9.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. https://app.cochat.ai/papers/10.1038/s41467-017-01385-8
The paper
Wang, P., Li, X., Wang, J., Gao, D., Li, Y., Li, H., Chu, Y., Zhang, Z., Liu, H., Jiang, G., Cheng, Z., Wang, S., Dong, J., Feng, B., Chard, L. S., Lemoine, N. R., & Wang, Y. (2017). Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nature Communications. https://doi.org/10.1038/s41467-017-01385-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.